Skip to main content
OpenTrials

Clinical trial condition

Recurrent Endometrial Endometrioid Adenocarcinoma

Explore clinical trials studying Recurrent Endometrial Endometrioid Adenocarcinoma. Study availability and eligibility vary by location and protocol.

7 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Recurrent Endometrial Endometrioid Adenocarcinoma trial results

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

NCT05950464

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +18 more
Locations
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
View all 14 locations
View Trial Details
Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

NCT02684227

Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, +6 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • The Woman's Hospital of Texas Houston, Texas, United States
  • MD Anderson in Katy Houston, Texas, United States
  • MD Anderson League City Nassau Bay, Texas, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612

Conditions
Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +30 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 397 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

NCT05538897

Conditions
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, +1 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States
  • Highlands Oncology Group - Rogers Rogers, Arkansas, United States
View all 152 locations
View Trial Details
Active, Not Recruiting

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

NCT03348631

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 582 locations
View Trial Details

Related conditions